Cuatro embajadores españoles continúan al frente de sus legaciones en capitales de primer orden —Washington y París entre ...

Enterprises are deploying agents faster than they can verify them. HashiCorp Vault uses Agent Identity to give each agent a ...

Fitbit trackers took a back seat while Google pushed the Pixel Watch, but the Fitbit Edge proves the dedicated fitness ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...

Long-Term OS Results With Lenvatinib Plus Pembrolizumab and TACE in HCC / cancer, cancer care, Cancer research, cancer ...

ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting - ...

In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee (IDMC), HARMONi-GI1 met its primary ...

In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...

And divarasib reduced the risk for death by 44% during the trial, with a median overall survival (OS) of 17.7 versus 12 ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...

As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of ...